New hope for kids with rare brain tumors: experimental drug enters human testing
NCT ID NCT07158710
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-stage trial tests an oral drug called HSK42360 in children aged 6 to 17 with recurrent malignant brain tumors that have a specific BRAF V600 mutation. The study aims to find the safest dose and check for side effects, while also looking at whether the drug can shrink tumors. About 159 children who have already tried standard treatments without success will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK42360 (oral drug)
What this could lead to
If successful, this could point toward a new treatment option for children with hard-to-treat BRAF-mutant brain tumors.
What could go wrong
This is a very early Phase 1 trial with only 159 participants. The main goal is safety, not proof of effectiveness, and the drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Affiliated Huashan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The first affiliated hospital of fujian medical university
RECRUITINGFuzhou, Fujian, 350200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510280, China
Contact Phone: •••-•••-•••• Email: •••••@•••••